1

# Title: Epidemiology, clinical presentation and management of COVID-19 associated Mucormycosis: A single center experience from Pune, Western India.

4

Authors: Ameet Dravid MD<sup>1</sup>, Reema Kashiva MD<sup>2</sup>, Zafer Khan MD<sup>3</sup>, Balasaheb Bande 5 <sup>3</sup>, Danish Memon MD<sup>2</sup>, Aparna Kodre MD<sup>2</sup>, Prashant Potdar MD<sup>2</sup>, Milind Mane MD<sup>3</sup>, 6 Asir Tamboli MD<sup>3</sup>, Vishal Pawar MD<sup>3</sup>, Dattatraya Patil MD<sup>3</sup>, Debashis Banerjee MD<sup>3</sup>, 7 Kailas Bhoite<sup>3</sup>, Akshay Shinde MD<sup>3</sup>, Reshma Pharande MBBS<sup>3</sup>, Suraj Kalyani MBBS<sup>3</sup>, 8 Prathamesh Raut MBBS<sup>3</sup>, Madhura Bapte MD<sup>3</sup>, Charlotte Saldanha MD<sup>3</sup>, Dinesh 9 Chandak MD<sup>3</sup>, Fouzia Ajani MD<sup>3</sup>, Anshul Mehta MBBS<sup>2</sup>, M Sateesh Reddy MBBS<sup>2</sup>, 10 Krushnadas Bhayani MBBS<sup>2</sup>, S S Laxmi MBBS<sup>2</sup>, P D Vishnu MBBS<sup>2</sup>, Shipra Srivastava 11 MBBS<sup>2</sup>, Shubham Khandelwal MBBS<sup>2</sup>, Sailee More MBBS<sup>2</sup>, Atif Shakeel MBBS<sup>2</sup>, 12 Mohit Pawar MBBS<sup>2</sup>, Pranava Nande MBBS<sup>2</sup>, Amol Harshe MD<sup>4</sup>, Sagar Kadam MD<sup>5</sup>, 13 Sudhir Hallikar MD<sup>6</sup>, Nudrat Kamal MD<sup>6</sup>, Danish Andrabi MD<sup>6</sup>, Sachin Bodhale MD<sup>7</sup>, 14 Akshay Raut BDS<sup>8</sup>, Pushkar Gawande BDS<sup>8</sup>, Ankush Bhandari BDS<sup>8</sup>, Nilesh Wasmatkar 15 MD<sup>9</sup>, Adnanali Sarkar MD<sup>9</sup>, Sangeeta Chandrashekhar MD<sup>9</sup>, Pallavi Butivani MD<sup>9</sup>, 16 Geetanjali Akhade MD<sup>9</sup>, Aditi Abnave MD<sup>9</sup>, Chandrashekhar Raman MD<sup>10</sup>, Siraj 17 Basade MD<sup>10</sup>, Uma Mahajan M.Sc<sup>11</sup>, Gaurav Joshi MBA<sup>12</sup>, Dilip Mane MD<sup>2</sup> 18 **Author Affiliations:** 19 1 – Department of Infectious diseases and HIV/AIDS, Noble hospitals and Research Centre, 20 Pune, Maharashtra, India 21 2 – Department of Medicine, Noble hospital and Research Centre, Pune, Maharashtra, India 22 3 - Department of Critical Care Medicine, Noble hospital and Research Centre, Pune, 23 Maharashtra, India 24 4 – Department of Pathology, Noble hospital and Research Centre, Pune, Maharashtra, India 25 5 - Department of Radiology, Noble hospital and Research Centre, Pune, Maharashtra, India 26

27 6 – Department of Otorhinolaryngology, Noble hospital and Research Centre, Pune,
28 Maharashtra, India

- 29 7 Department of Ophthalmology, Noble hospital and Research Centre, Pune, Maharashtra,
- 30 India
- 31 8 Department of Maxillo-facial surgery, Noble hospital and Research Centre, Pune,
- 32 Maharashtra, India
- 33 9 Department of Anesthesia, Noble hospital and Research Centre, Pune, Maharashtra, India
- 10- Department of Neurosurgery, Noble hospital and Research Centre, Pune, Maharashtra, India
- 35 11 Statistician, VMK Diagnostics private limited, Pune, Maharashtra, India.
- 36 12 Independent statistical consultant, Chicago, USA.
- 37

## 38 Email addresses of authors:

Ameet Dravid – ameet.dravid@gmail.com, Reema Kashiva – reemakashiva@gmail.com, Zafer 39 Khan – zafer a khan@yahoo.co.in, Balasaheb Bande – drbandebd@hotmail.com, Danish 40 Memon – danish1331@yahoo.co.in, Aparna Kodre – draparnankodre@gmail.com, Prashant 41 Potdar - pashya2511@gmail.com, Milind Mane - drmilind.mane@gmail.com, Asir Tamboli -42 drasirtamboli@gmail.com, Vishal Pawar – dr.vishal.d.pawar@gmail.com, Dattatraya Patil – 43 drdattapatil05@gmail.com, Debashis Banerjee – debaz2009@gmail.com, Kailas Bhoite – 44 kailasbhoite1978@gmail.com, Akshay Shinde – dr.akshay7@gmail.com, Reshma Pharande – 45 reshma.pharande97@gmail.com, Suraj Kalyani – surajkalyani@gmail.com, Prathamesh Raut – 46 rautlesh@gmail.com, Madhura Bapte – madhuraparth@gmail.com, Charlotte Saldanha – 47 charlotte2491@gmail.com, Dinesh Chandak - dineshchandak444@gmail.com, Fouzia Ajani -48 drfouziahirani@gmail.com, Anshul Mehta - anshroks.25@gmail.com, M Sateesh Reddy -49 50 satishat321@gmail.com, Krushnadas Bhayani - kbhayani321@gmail.com, S S Laxmi drsslakshmiatl@gmail.com, P D Vishnu - p.d\_vishnu@yahoo.co.in, Shipra Srivastava -51 srivastavashipra51@gmail.com, Shubham Khandelwal - shubh.joyrider@gmail.com, Sailee 52 More – drsaileemore@gmail.com, Atif Shakeel – khanaatif009@gmail.com, Mohit Pawar – 53 mohitpawar2915@gmail.com, Pranava Nande - pranavanande4@gmail.com, Amol Harshe -54 dramolh@yahoo.co.in, Sagar Kadam - drsagarkadam@gmail.com, Sudhir Halikar -55 56 halikarsudhir@gmail.com, Nudrat Kamal- nudratkamal86@gmail.com , Danish Andrabi – danish andrabi@yahoo.co.in, Sachin Bodhale - drsrb1@gmail.com, Akshay Raut -57 58 akshavraut8@gmail.com, Pushkar Gawande – gawandepushkar@gmail.com, Ankush Bhandari –

It is made available under a CC-BY-NC-ND 4.0 International license .

dr.ankushbhandari@yahoo.com, Nilesh Wasmatkar - drnileshkw@gmail.com, Adnanali Sarkar

- adnansarkar2@gmail.com, Sangeeta Chandrashekhar - drsangeet15@rediffmail.com, Pallavi

59

60

61	Butiyani – pallavibutiyani@gmail.com, Geetanjali Akhade – dangat.geeta@gmail.com, Aditi
62	Abnave – abnaveaditi@gmail.com, Chandrashekhar Raman – drshekhar71@hotmail.com, Siraj
63	Basade - siraj582@yahoo.com, Uma Mahajan - umasmahajan@gmail.com , Gaurav Joshi -
64	gaurav.arun.joshi@gmail.com, Dilip Mane – <u>dileep.mane@yahoo.co.in</u> .
65	
66	Corresponding Author – Ameet Dravid, Email – ameet.dravid@gmail.com
67	
68	Abbreviations:
69	Severe acute respiratory syndrome coronavirus 2 - SARS-CoV-2; coronavirus disease 2019-
70	COVID-19; World health organization - WHO; COVID-19 associated Mucormycosis - CAM;
71	C-reactive protein - CRP; lactate dehydrogenase - LDH; Interleukin - 6 - IL-6; Interferon
72	Gamma - IFN-y; diabetes mellitus - DM; Tocilizumab - TCZ; cytokine release syndrome - CRS;
73	diabetic ketoacidosis - DKA; Rhino-orbito-cerebral mucormycosis - ROCM; Noble hospital and
74	Research Centre - NHRC; High resolution computerized tomography scan - HRCT ; oxygen
75	saturation - $SpO_2$ ; ratio of arterial partial pressure of oxygen to fraction of inspired oxygen-
76	PaO <sub>2</sub> /FiO <sub>2;</sub> Functional endoscopic paranasal sinus surgery - FESS; Liposomal Amphotericin B -
77	LAmB; reverse transcription PCR- RT-PCR; Intensive care unit - ICU; Central nervous system -
78	CNS; institutional review board - IRB; interquartile range - IQR; absolute neutrophil count -
79	ANC ; absolute lymphocyte count - ALC; Intravenous - IV; acute respiratory distress syndrome
80	– ARDS.
81	
82	
83	
84	
85	
86	
87	
88	

#### 89 Abstract:

Background: The second COVID-19 wave in India, triggered by the Delta variant, has been 90 unprecedented increase in cases 91 associated with an of COVID-19 associated Mucormycosis(CAM), mainly Rhino-orbito-cerebral mucormycosis(ROCM). The primary reason 92 93 appears to be an unusual alignment of multiple risk factors in patients like prevalence of hypoxia, uncontrolled diabetes mellitus, indiscriminate use of steroids, high iron levels and immune 94 95 dysfunction.

96 Methods: This retrospective cohort study was conducted at Noble hospital and Research Centre 97 (NHRC), Pune, Western India between 1<sup>st</sup> April 2020 and 1<sup>st</sup> August 2021 to identify patients 98 admitted with CAM. The primary endpoint was incidence of all cause mortality due to CAM. 99 Secondary outcomes studied were need for mechanical ventilation and intensive care unit(ICU) 100 admission. Baseline and time dependent risk factors significantly associated with death due to 101 CAM were identified by Relative risk estimation.

Results: 59 patients were diagnosed with Mucormycosis at NHRC (58 ROCM, 1 Renal 102 (disseminated) mucormycosis). Median age of the cohort was 52(IOR: 41,61) years and it 103 included 20.3% females. Median duration from first positive COVID-19 RT PCR test to 104 105 diagnosis of Mucormycosis was 17(IQR: 12,22) days. 90% patients were diabetic with 30% being newly diagnosed at the time of COVID-19 admission and 89% having uncontrolled sugar 106 level (HbA1c > 7%). All patients were prescribed steroids during treatment for COVID-19. 56% 107 patients were prescribed steroids for non-hypoxemic, mild COVID (irrational steroid therapy) 108 while in 9%, steroids were indicated but were prescribed in inappropriately high dose. Majority 109 of the patients were treated with a combination of surgical debridement(94%), intravenous 110 Amphoteric B(91%) and concomitant oral Posoconazole therapy (95.4%). 74.6% patients were 111 discharged after clinical and radiologic recovery while 25.4% (15 patients) died. On Relative risk 112 analysis, CT severity score during COVID-19 admission  $\geq 18$  (p=0.017), presence of orbital 113 114 symptoms(p=0.002), presence of diabetic ketoacidosis(p=0.011) and cerebral involvement by Mucor(p=0.0004) were associated with increased risk of death. Duration of Amphotericin B 115 116 therapy of  $\geq 21$  days was associated with statistically significant reduction in mortality(p=0.002).

117	Conclusions: CAM is an uncommon, rapidly progressive, angioinvasive, opportunistic fungal
118	infection which is fatal if left untreated. Combination of surgical debridement and antifungal
119	therapy leads to clinical and radiologic improvement in majority of cases.
120	
121	
122	
123	
124	
125	
126	
127	
128	
129	
130	
131	
132	
133	
134	
135	
136	
137	
138	
139	
140	
141	
142	

It is made available under a CC-BY-NC-ND 4.0 International license .

6

## 143 **Introduction:**

In December 2019, Wuhan city, the capital of Hubei province in China, became the 144 centre of an outbreak of viral pneumonia. By Jan 7, 2020, scientists had isolated a novel RNA, 145 146 beta coronavirus from these patients. It was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to its sequence homology with SARS-COV-1<sup>[1]</sup>. The disease 147 caused by SARS-COV-2 was later designated coronavirus disease 2019 (COVID-19) in 148 February 2020, by World health organization (WHO)<sup>[2]</sup>. COVID-19 spread rapidly worldwide 149 and India was no exception. By 1<sup>st</sup> August 2021, there have been more than 300 million 150 infections and 0.4 million deaths due to COVID-19 in India<sup>[3]</sup>. With COVID-19, the incidence 151 of secondary bacterial or fungal infections is 8%, with aspergillosis and candida being the most 152 common fungi reported <sup>[4,5]</sup>. The second COVID wave in India (March 2021 – May 2021). 153 154 triggered by the Delta variant, has also been associated with an unprecedented increase in the cases of COVID-19 associated Mucormycosis (CAM) <sup>[6,7]</sup>. Globally, the prevalence of 155 mucormycosis varies from 0.005 to 1.7 per million population, while its prevalence is nearly 80 156 times higher (0.14 per 1000) in India as per a recent estimate of year 2019-2020<sup>[7-9]</sup>. Thus, India 157 already had the highest cases of mucormycosis in the world and the incidence increased 158 159 exponentially during the second COVID wave. As of August 1<sup>st</sup>, 2021, 45,374 cases of CAM have been reported in India<sup>[6]</sup>. 160

CAM is an uncommon, rapidly progressive, angio-invasive, commonly fatal, 161 opportunistic fungal infection<sup>[9]</sup>. Unusual alignment of multiple risk factors could be associated 162 with sudden spurt of CAM in India <sup>[10]</sup>. Dysregulated immune response in COVID-19 163 characterized by exuberant activation of innate immune system, elevation in systemic 164 165 inflammatory markers (C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH) and Ddimer), aberrant pro-inflammatory cytokine secretion (Interleukin - 6 (IL-6), soluble IL-2 166 167 receptor [IL-2R], IL-10, TNF-α) by alveolar macrophages and depleted adaptive immune 168 response (decline in CD4+ T cell, CD8+ T cell, Natural killer cell and decreased Interferon Gamma (IFN-y) expression in CD4+ T cells) could be one of the factors predisposing individuals 169 to CAM<sup>[11,12]</sup>. In these patients, the activation of antiviral immunity to SARS-CoV-2 may, 170 171 paradoxically, potentiate an inflammatory phenotype and thus may favor secondary infections. In 172 addition, India has the second largest population with diabetes mellitus (DM) in the world (77

million people with diabetes, with a nationwide prevalence of 7.3 %.)<sup>[13, 14]</sup>. SARS-CoV-2 has 173 174 been shown to affect the beta cells of the pancreas, resulting in metabolic derangement, possibly causing diabetes mellitus <sup>[15]</sup>. Uncontrolled DM is a risk factor for both, COVID-19 and 175 Mucormycosis. Steroids, namely Dexamethasone and Methylprednisolone have been extensively 176 used to resolve hyperinflammation and inflammatory lung damage in severe COVID-19<sup>[16-18]</sup>. 177 178 But use of steroids can cause hyperglycemia, suppression of several polymorphonuclear (PMN) 179 leucocyte functions, impairment of phagocytosis by resident macrophages, depletion of T cell immunity<sup>[10]</sup> and increase risk of Mucormycosis. Indiscriminate use of steroids in patients with 180 181 mild or asymptomatic COVID-19 can be counter-productive and make the person susceptible to opportunistic fungi <sup>[19]</sup>. Use of immunomodulator therapy like Tocilizumab (TCZ, IL-6 receptor 182 inhibitor) in combination with steroids for Cytokine release syndrome (CRS, cytokine storm) 183 could further aggravate immunosuppression and facilitate breakthrough fungal infection<sup>[20]</sup>. 184 Thus, the primary reason for this sudden increase in CAM in India appears to be germination of 185 Mucorales spores in an ideal environment of low oxygen (hypoxia), high glucose (diabetes 186 187 mellitus, new onset hyperglycemia, impaired fasting glucose or steroid-induced hyperglycemia), acidic environment<sup>[10]</sup> (metabolic acidosis, diabetic ketoacidosis [DKA]), high iron levels (hyper-188 ferritinemia characteristic of COVID-19 leading to excess intracellular iron that generates 189 190 reactive oxygen species and resultant death of cells with acidosis facilitating free iron release for mucor germination)<sup>[21,22]</sup> and immune dysfunction (mediated by Delta variant of SARS COV-2, 191 steroid therapy or background co-morbidities). 192

The most common form of Mucormycosis seen in India during the COVID-19 pandemic 193 was the Rhino-orbito-cerebral (ROCM) one but cases of pulmonary <sup>[7,23]</sup> or disseminated 194 mucormycosis <sup>[24]</sup> have also been reported. Suspected ROCM requires urgent intervention, 195 because of the often rapidly progressive and destructive nature of the infection. Delayed 196 initiation of therapy is associated with increased mortality <sup>[25,26]</sup>. Despite treatment, case-fatality 197 rates due to mucormycosis during the pre-COVID-19 pandemic era were already high, ranging 198 from 32% to 70%, according to organ involvement <sup>[25,26]</sup>. However, in SARS-CoV-2 infection, 199 200 the mortality maybe even higher. Maximizing survival rates requires rapid diagnostic and therapeutic intervention, including immediate involvement of a multidisciplinary medical, 201 surgical, radiological, and laboratory-based team. Multiple case reports <sup>[27-50]</sup> and retrospective 202

cohort studies <sup>[7, 51-61]</sup> of CAM from India and other countries have already been published. 203 204 However, detailed epidemiology, risk factor analysis, surgical and medical treatment 205 administered, outcomes and complications (especially long-term complications) developing in these patients has been scarcely reported <sup>[7,52,57]</sup>. In addition, lack of imaging modalities in rural 206 areas of India, inability to identify early symptoms by general practitioners, shortage of 207 208 antifungal drugs (especially Liposomal Amphotericin B) during second COVID wave and 209 inadequate number of specialists to perform complex endoscopic, orbital and skull base surgeries <sup>[7,10]</sup> posed a serious challenge in tackling rising ROCM cases in India and led to a high mortality 210 in certain cohort studies <sup>[7,52]</sup>. As a result, we planned this retrospective observational cohort 211 212 study aimed at understanding the epidemiology, clinical presentation, outcomes and long-term 213 complications in patients with CAM admitted at our tertiary level hospital in Pune, Western India during the COVID-19 pandemic. 214

#### 215 **Methods:**

#### 216 Study Setting:

This retrospective cohort study was conducted at Noble hospital and Research Centre 217 (NHRC), Pune, Western India. NHRC is a tertiary level private hospital designated for clinical 218 management of COVID-19 patients and management of post COVID complications since 23rd 219 March 2020. Pune is located in the state of Maharashtra, Western India and was one of the 220 epicenters of COVID-19 epidemic in India. As of 1<sup>st</sup> August 2021, Maharashtra state has 221 reported more than 6.3 million cases of COVID-19 and more than 133.000 deaths <sup>[3]</sup>. Till 1<sup>st</sup> 222 August 2021, NHRC has admitted 5439 COVID-19 patients with 391 deaths. Maharashtra state 223 has also reported more than 5000 cases of COVID-19 associated Mucormycosis (CAM) till 1st 224 August 2021<sup>[6]</sup>. 225

NHRC provides clinical care, diagnostic and treatment services to patients at a subsidized
 cost. Data of all hospitalized patients is entered into an electronic database (Lifeline electronic
 database, Manorama infosystems, Kolhapur, India).

#### 229 **Study Population:**

Patients were eligible for inclusion in this analysis if they were admitted to NHRC between 1<sup>st</sup> April 2020 and 1<sup>st</sup> August 2021 and were diagnosed with COVID-19 associated Mucormycosis (CAM). COVID-19 diagnosis was made in patients who tested positive for SARS

233 COV 2 RNA in respiratory specimens by reverse transcription PCR (RT-PCR) or a positive rapid 234 antigen test. Mucormycosis was identified in patients having compatible clinical and radiologic 235 manifestations and demonstration of fungi in the tissue or sterile body fluids by either direct 236 microscopic visualization of broad ribbon-like aseptate hyphae (potassium hydroxide (KOH) 237 mount or Calcofluor stain), culture isolation of Mucorales (Sabouraud dextrose agar) or 238 Histopathology examination of affected tissue showing Mucor species (Hematoxylin and eosin, periodic acid Schiff, or Gomori methenamine silver stain)<sup>[9]</sup>. CAM was defined as development 239 of Mucormycosis within 3 months of diagnosis of COVID-19. 240

241 Data was obtained from electronic health record of each individual admitted for treatment 242 of CAM in NHRC by manual abstraction. It included hospitalization dates, demographics, comorbidities, severity of associated COVID-19 illness, treatment received for COVID-19 243 including steroids and immunomodulator therapy, presenting symptoms of Mucormycosis, 244 clinical examination data, anatomic site of involvement, diagnostic modalities including 245 microscopy, culture, or histopathology, laboratory investigation data (including inflammatory 246 247 markers), microbiology reports, imaging reports (High resolution computerized tomography scan of chest, paranasal sinuses and brain (HRCT chest, CT PNS and CT brain)), treatment details, 248 249 including antifungal drug therapy and surgical debridement, data on use of supplemental oxygen, 250 mechanical ventilation and hospitalization outcomes. Mild COVID was defined as individuals 251 who have various signs and symptoms of COVID-19 but who do not have shortness of breath, dyspnea, or abnormal chest imaging <sup>[62]</sup>. Moderate disease was defined as patients who show 252 evidence of lower respiratory disease during clinical assessment or imaging and who have 253 254 oxygen saturation (SpO<sub>2</sub>) 90 to  $\leq$  93% on room air. Severe COVID was defined as SpO<sub>2</sub> < 90% on room air, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen 255  $(PaO_2/FiO_2) < 300 \text{ mm Hg}$ , respiratory frequency > 30 breaths/min or lung infiltrates >50% <sup>[62]</sup>. 256 Critical COVID was defined as presentation with respiratory failure, septic shock, and/or 257 multiple organ dysfunction. For all patients diagnosed with CAM, we also scrutinized inpatient 258 case files until hospital discharge, death, or 1<sup>st</sup> September 2021—the date on which the database 259 260 was locked—whichever happened first. Systemic complications developing in patients during 261 hospital admission were also noted. All patients who died due to CAM during hospital admission 262 were identified and a death audit to look for complications and cause of death was undertaken.

It is made available under a CC-BY-NC-ND 4.0 International license .

10

For patients who left the hospital against medical advice, we considered a worst-case scenario for mortality analysis and assumed the patients died. All patients who recovered, got discharged from NHRC and had outpatient follow-up at 15, 30 and 90 days after discharge were identified. Their outpatient follow-up visits were traced from electronic database to look for delayed complications.

## 268 Management of Mucormycosis at NHRC:

NHRC protocol for management of Mucormycosis has been developed after careful consideration of current global and national guidelines <sup>[63,64]</sup>. As per the protocol, early, radical, surgical debridement of affected site in addition to combination systemic antifungal therapy was utilized for treatment.

#### 273 Surgical management:

274 Functional endoscopic paranasal sinus surgery (FESS) with debridement of necrosed and 275 diseased sinus tissue and orbital decompression was the most common surgical procedure performed in patients with ROCM. All efforts were made to preserve the eye for as long as 276 277 possible in view of role of eye to not only provide vision but also its removal causing significant psycho-social problems to patient. In patients with total blindness, proptosis, fixed pupil and 278 279 eyeball, imaging evidence of orbital involvement by Mucor (globe/muscles/fat) and/or intracranial spread (superior orbital fissure/inferior orbital fissure involvement), surgical 280 exenteration of the eye was performed <sup>[65]</sup>. Surgical exenteration of the eye with debridement of 281 orbital cavity was performed in consultation with Department of Otorhinolaryngology and 282 Ophthalmology. Partial or total maxillectomy was performed in patients with evidence of 283 osteomyelitis of maxilla or alveolar arch. Neurosurgery was performed in case of intracranial 284 285 spread of disease with involvement of skull base or formation of basi-frontal lobe brain abscess.

#### 286 Medical management:

287 Combination therapy of Liposomal Amphotericin B (LAmB) and Oral Triazole 288 (predominantly oral Posaconazole) was the most common medical treatment offered to all 289 patients with CAM. LAmB was initiated at the dose of 5 mg/kg. The dose was increased to 10 290 mg/kg in case of intracranial spread <sup>[63,64]</sup>. In the scenario of shortage of LAmB due to surge in 291 CAM cases or non affordability of patient, other formulations of Amphotericin B (Amphotericin 292 B lipid complex (5 mg/kg), Amphotericin B lipid emulsion (5 mg/kg) and Amphotericin B de-

293 oxycholate (1 mg/kg)) were used for patients. The duration of Amphotericin B treatment was 294 decided depending on the site of involvement (3 weeks for only paranasal sinus involvement, 4 weeks for orbital, lung and disseminated Mucormycosis and 6 weeks for Central nervous system 295 (CNS) Mucormycosis). Oral Posaconazole (delayed release tablets, 300 mg twice a day on Day 1 296 297 and then 300 mg once a day) was started along with Amphotericin B treatment and continued 298 after discharge from hospital for a period of 1 to 3 months depending on local control of disease 299 and discretion of Infectious disease physician. In patients with concomitant chronic kidney disease, intravenous Posaconazole or Isavuconazole followed by step-down to oral therapy was 300 301 treatment of choice. Serum Posaconazole levels were performed to guide dosage during oral therapy. 302

#### 303 **Outcomes:**

304 Primary endpoint:

305 1) Deaths in the cohort due to CAM.

306 Secondary outcomes:

- 307 2) Number of patients who had a clinical and radiologic recovery and were discharged from
   308 hospital.
- 309 3) Patients who required mechanical ventilation (noninvasive or invasive) and Intensive care
  310 unit (ICU) admission for CAM.
- 4) Incidence of systemic complications (including long-term complications) in patients after
   starting Amphotericin B therapy.
- The use of database for clinical research was approved by the institutional review board (IRB) of Noble hospital and Research Centre, Pune, India.

# 315 Statistical Methods:

Continuous variables were summarized using median and interquartile range (IQR), while categorical variables were summarized using frequency and percentages. Continuous variables were compared using a Mann Whitney U test. Categorical variables were compared using Chi-square test, Proportion test and Fishers' exact test. Baseline and time dependent risk factors significantly associated with death due to CAM were identified by Relative risk analysis. Baseline risk factors included for analysis were age (< 60 years or  $\geq$  60 years), gender, severity of baseline COVID disease (CT severity index  $\geq$  18 versus < 18), presence of orbital or central

323 nervous system (CNS) symptoms, presence of diabetic keto-acidosis, presence of intracranial 324 spread (cerebral involvement) and baseline investigations like absolute lymphocyte count (< 1000 versus  $\geq$  1000 cells/mm<sup>3</sup>), C reactive protein ( $\geq$  50 versus < 50 mg/L), D-dimer ( $\geq$  252 325 versus < 252 mcg/mL) and Ferritin ( $\geq 1000 \text{ versus} < 1000 \text{ mcg/L}$ ). Time dependent risk factors 326 327 included duration of Amphotericin B therapy (< 3 weeks versus  $\geq$  3 weeks) and development of 328 systemic complications like acute kidney injury, hepatitis, anemia, thrombocytopenia, 329 osteomyelitis and CNS complications (stroke or cerebritis). The p value  $\leq 0.05$  was considered as statistically significant. All data was analyzed by SPSS version 12.0. 330

## 331 **Results:**

During the period between 1<sup>st</sup> April 2020 to 1<sup>st</sup> August 2021, 59 patients were diagnosed 332 333 with Mucormycosis at NHRC. Fifty-eight patients were diagnosed to have ROCM while 1 patient was diagnosed to have Renal (disseminated) mucormycosis. Median age of the cohort 334 335 was 52 (IQR: 41, 61) years and it included 20.3 % (12/59) females. Seventeen (28.8 %) patients were > 60 years of age. Fifty-six (95 %) patients had pre-existing or newly diagnosed co-336 morbidities. Diabetes mellitus (53/59, 89.8 %) was the most common co-morbidity seen in our 337 cohort. Of these, 15 patients (28.3 %) were newly diagnosed with diabetes during hospital 338 339 admission for COVID-19. Two patients were diagnosed to have impaired fasting glucose (Fasting blood glucose between 110 and 125 mg/dl). Preexisting co-morbidities observed in 340 341 patients at admission are enumerated in Table 1. Three patients (5.1%) had no co-morbidities prior to developing CAM. 342

Clinically, 16 patients (27.1%) had mild COVID, 29 (49.2 %) had moderate COVID and 343 14 patients (23.7%) had severe or critical COVID disease prior to diagnosis of Mucormycosis. 344 All 59 patients underwent High resolution CT (HRCT) imaging of chest (GE Optima, 128 slice 345 CT scanner) during admission for COVID-19 and median CT severity index was 12 (IQR: 346 8,14.5). CT severity index <sup>[66]</sup> indicated mild disease (CT severity index: < 8) in 18.6 % (11/59), 347 348 moderate disease (CT severity index: 8-14) in 56 % (33/59) and severe disease (CT severity index: 15-25) in 25.4 % (15/59) of patients. Treatments given during COVID-19 admission are 349 enumerated in Table 2a and 2b. Remdesivir was prescribed to 67.8 % (40/59), intravenous and/or 350 351 oral steroids were prescribed to 100 % and Immune-modulator therapy (Tocilizumab - 5, 352 Barcitinib-2, Idofinib-1, Infliximab-2, Bevacizumab - 2 and Itolizumab - 1) was prescribed to

353 22 % (13/59) patients in our cohort. Methylprednisolone was the commonest prescribed steroid 354 (54 patients, 91.5%, Table 2b). Most commonly prescribed dose of Methylprednisolone was 1-2 mg/kg/day in divided doses for 5 to 10 days <sup>[67]</sup>. Ten patients (16.9 %) were prescribed 2 355 different steroids during treatment course for COVID-19. 56 % (33/59) patients were prescribed 356 357 steroids in the absence of hypoxia (irrational or unscientific steroid use). In 5 (5/54, 9.3%) 358 patients, Methylprednisolone dose of more than 2 mg/kg/day was prescribed for treatment of 359 severe COVID-19 (wrong or excess steroid dose). Eleven patients (18.6%) required ICU admission while 7 (11.9 %) needed noninvasive or invasive ventilation during hospital admission 360 361 of COVID-19 infection. Thirteen patients (22%) had received COVID vaccination prior to 362 admission (3 patients received 2 vaccine doses and 10 patients received single vaccine dose, 363 Table 1). Five patients (8.5 %) were treated for COVID-19 while in home quarantine and did not require hospital admission. All 5 patients in home guarantine received steroids (irrational or 364 unscientific steroid use) as a part for of their treatment regimen. Median duration of hospital 365 admission for COVID-19 was 9 (IQR: 6, 14) days. 366

Median duration from first positive COVID-19 RT PCR test to diagnosis of 367 Mucormycosis was 17 (IQR: 12, 22) days. Duration was less than 14 days for 22 (37.3 %, early 368 369 CAM) patients while it was > 14 days for 37 (62.7 %, late CAM) patients. Median duration 370 between hospital discharge for COVID-19 to re-admission for Mucormycosis was 7 (IQR: 2.5, 371 15.5) days. Twenty patients (33.9 %) were diagnosed to have Mucormycosis (suspected fungal sinusitis, ROCM) during admission for COVID-19. Twenty-seven (45.7 %) were re-admitted 372 373 less than 14 days after hospital discharge for COVID-19 while 12 (20.4 %) were re-admitted after more than 14 days. Headache (43/58, 74.1 %), hemi-facial pain predominantly maxillary 374 375 pain (42/58, 72.4 %) and facial swelling (33/58, 56.9 %) were the three commonest presenting symptoms of ROCM in our cohort (Table 3). Median duration of symptoms was 6 (IOR: 3, 8.5) 376 377 days. Seven patients (11.9 %) had symptoms for more than 2 weeks prior to diagnosis of ROCM. Fifty-eight patients (99%) had rhinal (paranasal sinus) involvement, 33 (56%) had orbital 378 (eyeball, extra-ocular muscles or orbital cavity) and 26 (44.1%) had cerebral involvement 379 (infarcts, cavernous sinus involvement, dural enhancement, frontal lobe abscess, osteomyelitis 380 and erosion of frontal bone, Table 3). Palatal involvement (palatal necrosis, black eschar or 381 palatal osteomyelitis) was observed in 13 (22 %) patients. Median hemoglobin value at diagnosis 382

of Mucormycosis was 13.4 (IQR: 11.4, 14.5) mg/dl (Table 4). Median absolute neutrophil count 383 (ANC) was 8100 (IQR: 5248, 11475) cells/mm<sup>3</sup> and median absolute lymphocyte count (ALC) 384 was 1350 (IQR: 1010, 1750) cells/mm<sup>3</sup>. Fourteen patients (24.6 %) had ALC < 1000 cells/mm<sup>3</sup> 385 while no patient had ANC < 1000 cells/mm<sup>3</sup> at admission. Median CRP at admission was 84.7 386 (IQR: 41,167, 45 patients) mg/L, median D-dimer was 483.5 (IQR: 253.7,1201, 37 patients) 387 388 mcg/mL, and median Ferritin value was 857.1 (IQR: 280.5, 1429, 32 patients) mcg/L. Thirteen 389 patients (40.6 %) had serum Ferritin level > 1000 mcg/L at admission while 11 patients had Ddimer > 1000 mcg/mL. Median HbA1C level in our cohort was 9.3 (IQR: 8, 12). Ten patients 390 391 (10/53, 18.9%) presented with diabetic ketoacidosis. Diagnosis of Mucormycosis was made by KOH/calcofluor white staining of nasal scrapings (25/59, 42.4%), culture (5/59, 8.5%) and 392 393 histopathologic examination of excised tissue from paranasal sinuses (57/59, 96.6%). Mixed 394 mould infection (mucormycosis and aspergillosis) was observed in 3 patients.

395 Aggressive surgical debridement of involved site and combination antifungal therapy was standard of care for all ROCM patients in our cohort. Empirical combination anti-fungal therapy 396 was started after radiologic evidence of invasive sinusitis, pending confirmatory diagnosis by 397 histopathology or culture. Various treatment modalities used in our cohort are mentioned in 398 399 Table 5. Intravenous (IV) formulations of Amphotericin B (Liposomal, Lipid-complex, Lipid 400 emulsion or Deoxycholate) were the mainstay of antifungal therapy and prescribed to 91.5% 401 (54/59) patients. In view of shortage of Liposomal Amphotericin B in India during the second COVID-19 wave, patients ended up getting a combination of Amphotericin B formulations as 402 403 per availability. Liposomal Amphotericin B was prescribed to 89.8 % (53/59) patients for a median duration of 15 (IQR: 11, 21) days. Amphotericin B de-oxycholate or Conventional 404 405 Amphotericin B was prescribed to 45.8% (27/59) patients for a median duration of 4 (IQR: 3, 9) days. The median duration of Amphotericin B exposure to patients in our cohort was 21 (IOR: 406 407 14, 27) days. All patients were also prescribed concomitant oral triazole therapy (Posaconazole (58/59, 98.3%) or Isavuconazole (5/59, 8.5%)) during admission and after discharge till clinician 408 was satisfied about local control of disease. Median duration for oral triazole therapy was 60 409 days. FESS with orbital decompression was performed on 94.9 % patients (56/59). Surgical 410 exenteration of the eye with debridement of orbital cavity was performed in 13 (22 %) patients. 411 Partial maxillectomy was performed in 9 (15.3 %) patients while Neurosurgery for frontal lobe 412

It is made available under a CC-BY-NC-ND 4.0 International license .

brain abscess drainage was performed in 5 (8.5 %) patients. Eight patients (13.6 %) required
invasive mechanical ventilation while 18 (30.5 %) required ICU admission for Mucormycosis.

415 Complications during antifungal therapy and hospital admission are mentioned in Table 416 6. Fever with chills (78 %), Thrombophlebitis (59.3 %), Hypokalemia (88.1 %), Anemia (57.6 417 %) and Nephrotoxicity (50.8 %) were the most common complications observed during hospital 418 admission. Central nervous system (CNS) complications (stroke/cerebritis/brain abscess) were 419 seen in 25.4 % patients. There were 14 deaths (23.7 %) in our cohort during first hospital admission for Mucormycosis. On Relative risk analysis, CT severity score during COVID-19 420 421 admission  $\ge 18$  (p = 0.017), presence of symptoms like eye swelling (p = 0.002), loss of vision (p 422 < 0.0001), ptosis (p = 0.005) and limb weakness (p = 0.001), presence of diabetic ketoacidosis (p = 0.011), cerebral involvement by Mucor (p = 0.0004) and development of CNS complications 423 like stroke (p < 0.0001) during antifungal therapy were associated with increased risk of death 424 (Table 7, Figure 1). Duration of Amphotericin B treatment of more than 21 days was associated 425 with decreased risk of death (p = 0.002) on Relative risk analysis (Table 7). All patients who 426 427 were discharged from hospital were followed up for a minimum period of 6 weeks to look for late complications. Three patients needed re-admission, 48, 54 and 37 days after first discharge 428 in view of re-appearance of symptoms and/or imaging evidence of progression of disease to the 429 CNS. All 3 patients needed repeat surgical debridement and additional Amphotericin B 430 treatment. They were successfully discharged the second time. Two patients also needed re-431 admission for osteomyelitis of maxilla and alveolar arch which needed partial maxillectomy and 432 placement of dental prosthesis. One patient who had undergone exentration of eye was 433 readmitted 90 days later for insertion of orbital prosthesis. One patient who had been treated for 434 435 cerebral mucormycosis (bilateral complete vision loss and multiple cerebral infarcts) with 42 436 days of high dose Liposomal Amphotericin B and Posaconazole was readmitted with aspiration pneumonia 12 days later and died. Cause of death was respiratory failure due to aspiration 437 pneumonia and acute respiratory distress syndrome (ARDS, Total deaths in cohort - 15, 25.4%). 438

## 439 **Discussion:**

We conducted a single-centre, retrospective cohort study of 59 patients with CAM who were admitted at NHRC in the last 15 months. 74.6% patients could be successfully discharged

It is made available under a CC-BY-NC-ND 4.0 International license .

16

442 after control of disease with combined surgical and medical approach. Mortality rate in our443 cohort at 6 weeks follow-up was 25.4 %.

444 Majority of the patients in our study were middle-aged (median age: 52 vears), of which nearly two-thirds were male. It has been hypothesized that the effect of estrogen might be 445 protective in systemic fungal infection, which could have led to lower incidence in females <sup>[68]</sup>. 446 Case series on CAM by Sharma et al <sup>[46]</sup>, described diabetes as a risk factor in 90% cases of 447 448 which 52% had uncontrolled disease. A systematic review of 101 cases of CAM by Singh et al <sup>[58]</sup> also noted that more than 80% cases had either pre-existing or new onset hyperglycaemia as a 449 450 risk factor. Our study has demonstrated similar findings in that 90 % of included patients were 451 diabetic with almost 30% being newly diagnosed with DM at the time of admission for COVID-452 19. Of the 56 patients who had HbA1c value available, 50 had uncontrolled DM (HbA1c > 7%). Median HbA1c in our cohort was 9.3% while it was 9.6% in the study by Sen et al <sup>[55]</sup>. Tight 453 control of blood sugar level among patients with Diabetes Mellitus/ COVID-19 co-infection 454 could help in reducing incidence of ROCM. 455

Both the RECOVERY trial <sup>[17]</sup> and WHO COVID-19 <sup>[69]</sup> guidelines clearly recommend 456 against usage of Corticosteroids in COVID-19 patients not requiring oxygen (absence of 457 hypoxia). Despite that, indiscriminate use of steroids in mild COVID-19 continues in India. The 458 underlying reasons include the sudden surge of cases during second COVID wave leading to 459 panic among general practitioners, inadequate time for triaging patients in busy outpatient 460 clinics, non evidence-based clinical practice, availability of over the counter steroids, shortage of 461 hospital beds and inadequate monitoring of the patients taking steroids. The improper use of 462 corticosteroids has been identified as an independent risk factor for CAM by the MucoCovi 463 network<sup>[7]</sup>. In their retrospective analysis of 187 Indian CAM patients, they found that 78% 464 (150/187) had received steroid therapy but only 33% patients had received steroids at appropriate 465 dosages. In 33 % patients (50/150), steroids were not indicated while among 30% (45/150) 466 patients steroids were indicated but were prescribed in inappropriately high dose<sup>[7]</sup>. In 467 comparison, in our study, 56 % patients were prescribed steroids for non-hypoxemic, mild to 468 469 moderate COVID illness (irrational steroid therapy) while in 8.5 % patients steroids were 470 indicated but were prescribed in inappropriately high dose. Thus there is an urgent need to stop

17

471 prescription of steroids in non-hypoxemic COVID-19 patients and to limit the dose and duration472 of steroids in hypoxic patients.

473 In our cohort, majority of the patients were treated with a combination of surgical 474 debridement (94%) and intravenous Amphotericin B therapy (91%). Mortality rate at 6 weeks follow-up was 25.4 % which is lower than what is reported by Pal et al <sup>[57]</sup> and Patel et al 475 (MucoCovi network - 6 week mortality rate of 38.3 % and 12 week mortality of 45.7 %)<sup>[7]</sup>. 476 Reasons for lower mortality in our cohort as compared to the MucoCovi network <sup>[7]</sup> could be 477 relatively younger population (median age 52 years versus 56.9 years), lower prevalence of 478 479 hypoxia during COVID-19 (44 % versus 56 %), lower pulmonary involvement due to 480 Mucormycosis (0 % versus 8.6 %), increased use of combination antifungal therapy (91% versus 50%) and higher use of combined surgical and medical approach (91% versus 71%). However, 481 presence of diabetic ketoacidosis (10.9 % versus 8.6 %) and prevalence of cerebral involvement 482 due to Mucor (44 % versus 23 %) was higher in our cohort than the MucoCovi study <sup>[7]</sup>. Both the 483 factors, presence of diabetic ketoacidosis (p = 0.011) and cerebral involvement with Mucor (p = 0.011) 484 485 0.0004) were associated with higher risk of mortality on Relative risk analysis. In patients with cerebral involvement due to Mucor, mortality rate was 50% which is 5 times higher than among 486 patients without cerebral involvement. On the other hand, duration of Amphotericin B therapy of 487 more than 21 days was associated with statistically significant reduction in mortality (p = 0.002). 488 Development of ROCM while the patient is still under active treatment for moderate or severe 489 COVID-19 may pose significant challenges in the management – specifically termination of 490 491 corticosteroids, and surgery under general anesthesia. This was reflected in the CT severity index > 18 (depicting severe COVID pneumonia) being a significant risk factor for increased risk of 492 death due to CAM (p = 0.017). Patients with ROCM also remain at risk for delayed 493 494 complications and may need re-admission with further surgical and anti-fungal treatment to resolve them. 495

## 496 **Limitations**:

497 Our study has several limitations. First, this is not a randomized controlled trial, and 498 therefore unmeasured confounding cannot be ruled out. Second, as for all retrospective studies, 499 some individuals diagnosed with Mucormycosis may be unreported leading to measurement bias 500 and underestimation of mortality due to CAM. Third, we collected data from a single centre in

India unlike other multicenter cohort studies <sup>[7, 52,54,55,57]</sup>. Fourth, an overwhelmed health care 501 502 system, inadequate workforce and lack of exhaustive reporting due to surge of cases during 503 second COVID wave could be responsible for underestimation of co-morbidities, presenting 504 symptoms and complications amongst patients in our cohort. Fifth, inflammatory markers like 505 Ferritin, CRP and D-dimer were not available for all patients in the cohort. Sixth, we did not look 506 for environmental factors causing healthcare-associated mucormycosis like contaminated 507 ventilation systems, air conditioners, and ongoing construction in our hospital. We did not estimate the burden of Mucormycetes spores in our hospital environment. We also didn't 508 509 investigate the link between risk factors like use of industrial oxygen during the COVID 510 pandemic, contaminated nebulizer fluids or inline humidifier tubing used in ventilator circuits and contaminated oxygen delivery systems with increased incidence of CAM in our cohort <sup>[10]</sup>. 511 Seventh, other unexplored factors, including genetic predisposition were not identified. 512

513 Despite these limitations, this retrospective cohort study adds to the growing body of 514 literature on epidemiology, management strategies, outcomes and long term complications due to 515 COVID-19 associated Mucormycosis (CAM).

#### 516 **Conclusions**:

COVID-19 associated Mucormycosis (CAM) is an uncommon, rapidly progressive, 517 angio-invasive, opportunistic fungal infection which is fatal if left untreated. The most common 518 519 form of CAM seen in our cohort was the Rhino-orbito-cerebral (ROCM) one. COVID-19 induced immune dysregulation, uncontrolled diabetes mellitus and indiscriminate use of steroids 520 may be the risk factors associated with the sudden surge in Mucormycosis cases in India during 521 the second wave. Clinicians should have a high index of suspicion for ROCM in patients 522 recovering from COVID-19, especially among patients with new or previously diagnosed 523 diabetes mellitus and clinical manifestations of headache, facial or orbital pain. Combination of 524 surgical debridement and intravenous Amphotericin B therapy leads to clinical and radiologic 525 526 improvement in majority of cases. Cerebral involvement by Mucor is associated with higher mortality. 527

## 528 Acknowledgements:

Manisha Ghate MD, PhD (National AIDS Research Institute (NARI), Pune, India) - edited themanuscript.

# 531 **References:**

- 1) Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus
  disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from
  the Chinese Center for Disease Control and Prevention. *JAMA*. 2020.
  https://doi.org/10.1001/jama.2020.2648
- 5362) Worldhealthorganization(WHO):Availableat537<a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-</a>at538guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.
- 3) World health organization (WHO) Coronavirus disease (COVID-19) dashboard.
  Available at: <u>https://covid19.who.int</u>.
- 4) Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M et al.
  Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To
  Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020 Dec 3; 71(9):24592468. doi: 10.1093/cid/ciaa530. PMID: 32358954; PMCID: PMC7197596.
- 5) Song G, Liang G, Liu W. Fungal Co-infections Associated with Global COVID-19
  Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia. 2020
  Aug; 185(4):599-606. doi: 10.1007/s11046-020-00462-9. Epub 2020 Jul 31. PMID:
  32737747; PMCID: PMC7394275.
- 5496) PressreleasefromGovernmentofIndiaat550https://pib.gov.in/PressReleasePage.aspx?PRID=1728153accessed July 21st, 2021.
- 7) Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R et al; MucoCovi 551 Network3. Multicenter Epidemiologic Study of Coronavirus Disease-Associated 552 Infect 553 Mucormycosis, India. Emerg Dis. 2021 Jun 4: 27 (9). doi: 10.3201/eid2709.210934. Epub ahead of print. PMID: 34087089. 554
- 8) Chakrabarti A, Kaur H, Savio J, Rudramurthy SM, Patel A, Shastri P et al. Epidemiology
  and clinical outcomes of invasive mould infections in Indian intensive care units (FISF

5. PMID: 30769292.

study). J Crit Care. 2019 Jun;51 :64-70. doi: 10.1016/j.jcrc.2019.02.005. Epub 2019 Feb

559	9) Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi (Basel). 2019
560	Mar 21; 5(1):26.
561	10) Narayanan S, Chua JV, Baddley JW. COVID-19 associated Mucormycosis (CAM): risk
562	factors and mechanisms of disease. Clin Infect Dis. 2021 Aug 22:ciab726. doi:
563	10.1093/cid/ciab726. Epub ahead of print. PMID: 34420052.
564	11) García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19.
565	Front Immunol. 2020 Jun 16; 11: 1441. <u>https://doi.org/10.3389/fimmu.2020.01441</u>
566	12) Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in
567	COVID-19: addressing a pharmacological challenge by targeting pathways triggered by
568	SARS-CoV-2. Signal Transduct Target Ther. 2020 May 29; 5(1):84.
569	https://doi.org/10.1038/s41392-020-0191-1
570	13) IDF Diabetes ATLAS Ninth Edition. 2019. https://diabe tesat las.org/ upload/resources/
571	material/20200 302_133351_IDFAT LAS9e -final -web. pdf#page=42&zoom=auto.
572	Accessed May 12, 2020.
573	14) Anjana RM, Deepa M, Pradeepa R, et al. Prevalence of diabetes and prediabetes in 15
574	states : results from the ICMR-INDIAB population-based cross-sectional study. Lancet
575	Diabetes Endocrinol.2017;5: 585-596.
576	15) Müller JA, Groß R, Conzelmann C, et al. SARS-CoV- 2 infects and replicates in cells of
577	the human endocrine and exocrine pancreas. Nat Metab. 2021; 3: 149-165.
578	https://doi.org/10.1038/s4225 5-021- 00347-1.
579	16) WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group,
580	Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC et al. Association
581	Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill
582	Patients With COVID-19: A Meta-analysis. JAMA. 2020 Oct 6; 324(13):1330-1341.
583	https://doi.org/10.1001/jama.2020.17023
584	17) RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell
585	JL, Linsell L et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary

It is made available under a CC-BY-NC-ND 4.0 International license .

586	Report. N Engl J Med. 2020 Jul 17: NEJMoa2021436.
587	https://doi.org/10.1056/NEJM0a2021436
588	18) Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet.
589	2003 Nov 29;362(9398):1828-38. doi: 10.1016/S0140-6736(03)14904-5. PMID:
590	14654323.
591	19) Rodriguez-Morales AJ, Sah R, Millan-Oñate J, Gonzalez A, Montenegro-Idrogo JJ,
592	Scherger S et al. COVID-19 associated mucormycosis: the urgent need to reconsider the
593	indiscriminate use of immunosuppressive drugs. Ther Adv Infect Dis. 2021 Jun 18;8:
594	20499361211027065. doi: 10.1177/20499361211027065. PMID: 34211710; PMCID:
595	PMC8216396.
596	20) Actemra (tocilizumab) Prescribing information. South San Francisco, CA: Genentech,
597	Inc; 2019.
F 0.0	21) Throhim AS, Spallharz D, Edwards I, Iron acquisition, a neural neuronactive on
598	21) Ibrahim AS, Spellberg B, Edwards J. Iron acquisition: a novel perspective on
599	mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008; 21: 620-625.
600	https://doi.org/10.1097/QCO.0b013 e3283 165fd1
601	22) Perricone C, Bartoloni E, Bursi R, et al. COVID-19 as part of the hyperferritinemic
602	syndromes: the role of iron depletion therapy. Immunol Res. 2020; 68 : 213-224.
603	https://doi.org/10.1007/s1202 6-020-09145-5.
604	23) Pasero D, Sanna S, Liperi C, Piredda D, Branca GP, Casadio L, Simeo R, Buselli A,
605	Rizzo D, Bussu F, Rubino S, Terragni P. A challenging complication following SARS-
606	CoV-2 infection: a case of pulmonary mucormycosis. Infection. 2020 Dec 17:1-6. doi:
607	10.1007/s15010-020-01561-x. Epub ahead of print. PMID: 33331988; PMCID:
608	PMC7745708.
609	24) Monte Junior ESD, Santos M, Ribeiro IB, et al. Rare and fatal gastrointestinal
610	mucormycosis (Zygomycosis) in a COVID-19 patient: a case report. Clin Endosc 2020;
611	53: 746–749.
612	25) Deutsch P.G., Whittaker J., Prasad S. Invasive and non-invasive fungal rhinosinusitis—a
613	review and update of the evidence. Medicina. 2019;55: 1-14.

It is made available under a CC-BY-NC-ND 4.0 International license .

614	26) Brunet K and Rammaert B. Mucormycosis treatment: recommendations, latest advances,
615	and perspectives. J Mycol Med 2020; 30: 101007.

- 616 27) Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, Puri GD, Chakrabarti
  617 A, Agarwal R. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case
  618 Report and Systematic Review of Literature. Mycopathologia. 2021 May;186(2):289619 298. doi: 10.1007/s11046-021-00528-2. Epub 2021 Feb 5. PMID: 33544266; PMCID:
- 620 PMC7862973.
- 621 28) Baskar HC, Chandran A, Reddy CS, Singh S. Rhino-orbital mucormycosis in a COVID622 19 patient. BMJ Case Rep. 2021 Jun 24;14(6):e244232. doi: 10.1136/bcr-2021-244232.
  623 PMID: 34167998; PMCID: PMC8230977.
- 29) Rao R, Shetty AP, Nagesh CP. Orbital infarction syndrome secondary to rhino-orbital
  mucormycosis in a case of COVID-19: Clinico-radiological features. Indian J
  Ophthalmol. 2021 Jun;69(6):1627-1630. doi: 10.4103/ijo.IJO\_1053\_21. PMID:
  34011758.
- 30) Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a
  patient with COVID-19. Am J Emerg Med 2021; 42: 264. e5–264.e8.
- 31) Placik DA, Taylor WL and Wnuk NM. Bronchopleural fistula development in the
  setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2
  pneumonia. Radiol Case Rep 2020; 15: 2378–2381.
- 633 32) Kanwar A, Jordan A, Olewiler S, et al. A fatal case of Rhizopus azygosporus pneumonia
  634 following COVID-19. J Fungi (Basel) 2021; 7: 174.
- 33) Dallalzadeh LO, Ozzello DJ, Liu CY, et al. Secondary infection with rhino-orbital
  cerebral mucormycosis associated with COVID-19. Orbit. Epub ahead of print 23 March
  2021. DOI: 10.1080/01676830.2021.1903044.
- 34) Johnson AK, Ghazarian Z, Cendrowski KD, et al. Pulmonary aspergillosis and
  mucormycosis in a patient with COVID-19. Med Mycol Case Rep 2021; 32: 64–67.
- 35) Zurl C, Hoenigl M, Schulz E, et al. Autopsy proven pulmonary mucormycosis due to
  Rhizopus microsporus in a critically ill COVID-19 patient with underlying
  hematological malignancy. J Fungi (Basel) 2021; 7: 88.

- 36) Khatri A, Chang KM, Berlinrut I, et al. Mucormycosis after coronavirus disease 2019
  infection in a heart transplant recipient case report and review of literature. J Mycol
  Med 2021; 31: 101125.
- 37) Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, RomeroGutierrez L. A Case of Fatal Rhino-Orbital Mucormycosis Associated With New Onset
  Diabetic Ketoacidosis and COVID-19. Cureus. 2021 Feb 5;13(2):e13163. doi:
  10.7759/cureus.13163. PMID: 33575155; PMCID: PMC7870113.
- 38) Bellanger AP, Navellou JC, Lepiller Q, et al. Mixed mold infection with Aspergillus
  fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome
  Coronavirus 2 (SARSCoV-2) patient. Infect Dis Now. Epub ahead of print 27 January
  2021. DOI: 10.1016/j. idnow.2021.01.010.
- 39) Ahmadikia K, Hashemi SJ, Khodavaisy S, et al. The double-edged sword of systemic
  corticosteroid therapy in viral pneumonia: a case report and comparative review of
  influenza associated mucormycosis versus COVID-19 associated mucormycosis.
  Mycoses. Epub ahead of print 16 February 2021. DOI: 10.1111/ myc.13256.
- 40) Karimi-Galougahi M, Arastou S and Haseli S. Fulminant mucormycosis complicating
  coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol. Epub ahead of print
  13 March 2021. DOI: 10.1002/alr.22785.
- 41) Veisi A, Bagheri A, Eshaghi M, et al. Rhinoorbital mucormycosis during steroid therapy
  in COVID-19 patients: a case report. Eur J Ophthalmol. Epub ahead of print 10 April
  2021. DOI: 10.1177/11206721211009450.
- 42) Meshram HS, Kute VB, Chauhan S, Desai S. Mucormycosis in post-COVID-19 renal
  transplant patients: A lethal complication in follow-up. Transpl Infect Dis. 2021. June
  3:e13663. <u>https://doi.org/10.1111/tid.13663</u> 10.1111/tid.13663 PMid: ;PMCiD: . <u>DOI</u>PMC PubMed
- 43) Mehta S and Pandey A. Rhino-orbital mucormycosis associated with COVID-19.
  Cureus 2020; 12: e10726.
- 44) Sen M, Lahane S, Lahane TP, et al. Mucor in a viral land: a tale of two pathogens.
  Indian J Ophthalmol 2021; 69: 244–252.

672	45) Sarkar S, Gokhale T, Choudhury SS, et al. COVID-19 and orbital mucormycosis. India
673	J Ophthalmol 2021; 69: 1002–1004.

- 46) Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease
  mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. Epub
  ahead of print 8 April 2021. DOI: 10.1017/S0022215121000992.
- 47) Saldanha M, Reddy R,Vincent MJ. Paranasal mucormycosis in COVID-19 patient.
  Indian J Otolaryngol Head Neck Surg. Epub ahead of print 22 April 2021. doi:
  10.1007/s12070-021-02574-0.
- 48) Revannavar SM, Supriya PS, Samaga L, et al. COVID-19 triggering mucormycosis in a
  susceptible patient: a new phenomenon in the developing world? BMJ Case Rep 2021;
  14: e241663.
- 49) Maini A, Tomar G, Khanna D, et al. Sino-orbital mucormycosis in a COVID-19 patient:
  a case report. Int J Surg Case Rep 2021; 82: 105957.
- 50) Krishna V, Morjaria J, Jalandari R, Omar F, Kaul S. Autoptic identification of
  disseminated mucormycosis in a young male presenting with cerebrovascular event,
  multi-organ dysfunction and COVID-19 infection. IDCases. 2021;25:e01172. doi:
  10.1016/j.idcr.2021.e01172. Epub 2021 May 28. PMID: 34075329; PMCID:
  PMC8161734.
- 51) Ravani SA, Agrawal GA, Leuva PA, et al. Rise of the phoenix: mucormycosis in
  COVID-19 times. Indian J Ophthalmol 2021; 69: 1563–1568
- 52) Selarka L, Sharma S, Saini D, Sharma S, Batra A, Waghmare VT et al. Mucormycosis
  and COVID-19: An epidemic within a pandemic in India. Mycoses. 2021 Jul 13. doi:
  10.1111/myc.13353. Epub ahead of print. PMID: 34255907.
- 53) Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, Uncontrolled diabetes and
  corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial
  region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. Epub ahead of
  print 6 March 2021. DOI: 10.1007/s12663-021-01532-1.
- 54) Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, Rezaie Y, Rajaeih
  S, Alijani N, Barac A, Abdollahi A, Khodavaisy S. Mucormycosis in patients with
  COVID-19: A cross-sectional descriptive multicentre study from Iran. Mycoses. 2021

Jun 7:10.1111/myc.13334. doi: 10.1111/myc.13334. Epub ahead of print. PMID:
34096653; PMCID: PMC8242414.

- 55) Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, et al. Epidemiology, clinical
  profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral
  mucormycosis in 2826 patients in India Collaborative OPAI-IJO Study on
  Mucormycosis in COVID-19 (COSMIC), Report 1. *Indian J Ophthalmol.* 2021;69
  (7):1670-1692. doi:10.4103/ijo.IJO\_1565\_21.
- 56) Ramaswami A, Sahu AK, Kumar A, Suresh S, Nair A, Gupta D et al. COVID-19
  associated Mucormycosis Presenting to the Emergency Department An Observational
  Study of 70 Patients. QJM. 2021 Jul 12: hcab190. doi: 10.1093/qjmed/hcab190. Epub
  ahead of print. PMID: 34254132.
- 57) Pal R, Singh B, Bhadada SK, Banerjee M, Bhogal RS, Hage N et al. COVID-19associated mucormycosis: An updated systematic review of literature. Mycoses. 2021
  Jun 16. doi: 10.1111/myc.13338. Epub ahead of print. PMID: 34133798.
- 58) Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic
  review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021 May
  21;15 (4):102146. doi: 10.1016/j.dsx.2021.05.019. Epub ahead of print. PMID:
  34192610; PMCID: PMC8137376.
- 59) Mishra Y, Prashar M, Sharma D, Akash Kumar VP, Tilak TVSVGK. Diabetes, COVID
  19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center
  in Western India. Diabetes Metab Syndr. 2021 Jul 3;15 (4):102196. doi:
  10.1016/j.dsx.2021.102196. Epub ahead of print. PMID: 34246939; PMCID:
  PMC8253699.
- 60) Kumari A, Rao NP, Patnaik U, Malik V, Tevatia MS, Thakur S et al. Management
  outcomes of mucormycosis in COVID-19 patients: A preliminary report from a tertiary
  care hospital. Med J Armed Forces India. 2021 Jul;77: S289-S295. doi:
  10.1016/j.mjafi.2021.06.009. Epub 2021 Jul 26. PMID: 34334896; PMCID:
  PMC8313063.
- 61) Dubey S, Mukherjee D, Sarkar P, Mukhopadhyay P, Barman D, Bandopadhyay M et al.
   COVID-19 associated rhino-orbital-cerebral mucormycosis: An observational study

732	from Eastern India, with special emphasis on neurological spectrum. Diabetes Metab
733	Syndr. 2021 Sep 1:102267. doi: 10.1016/j.dsx.2021.102267. Epub ahead of print.
734	PMCID: PMC8407938.
735	62) CLINICAL MANAGEMENT PROTOCOL: COVID-19. Government of India Ministry
736	of Health and Family Welfare Directorate General of Health Services (EMR Division).
737	Version 5. Published May 2021. Available at:
738	https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated0
739	<u>3072020.pdf</u> .
740	63) Guideline for management of Mucormycosis in Covid - 19 patients. Government of
741	India Ministry of Health and Family Welfare Directorate General of Health Services
742	(EMR Division). Available at:
743	https://dghs.gov.in/WriteReadData/News/202105171119301555988Mucormycosismana
744	gementinCovid-19.pdf
745	64) Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis
746	and management of mucormycosis: an initiative of the European Confederation of
747	Medical Mycology in cooperation with the Mycoses Study Group Education and
748	Research Consortium. Lancet Infect Dis 2019; 19: e405-e421.
749	65) Shah K, Dave V, Bradoo R, Shinde C, Prathibha M. Orbital Exenteration in Rhino-
750	Orbito-Cerebral Mucormycosis: A Prospective Analytical Study with Scoring
751	System. Indian J Otolaryngol Head Neck Surg. 2019; 71 (2):259-265.
752	doi:10.1007/s12070-018-1293-8.
753	66) Francone M, Iafrate F, Masci GM, Coco S, Cilia F, Manganaro Let al. Chest CT score in
754	COVID-19 patients: correlation with disease severity and short-term prognosis. Eur
755	Radiol. 2020 Dec; 30(12): 6808-6817. https://doi.org/10.1007/s00330-020-07033-y.
756	67) AIIMS/ICMR-COVID-19 National Task force/Joint monitoring group (Dte GHS).
757	Ministry of health and family welfare, Government of India. Clinical guidance for
758	management of adult COVID-19 patients. Published 17th May 2021. Available at:
759	https://covid.aiims.edu/clinical-guidance-for-management-of-adult-covid-19-patients/
760	68) Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RLet al.
761	Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect

762	Dis. 2005 Sep 1; 41(5):634-53. doi: 10.1086/432579. Epub 2005 Jul 29. PMID:
763	16080086.
764	69) World health organization (WHO): COVID-19 Clinical management: living guidance.
765	Accessed 1 <sup>st</sup> September 2021. Available at:
766	https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1
767	
768	
769	
770	
771	
772 772	
773 774	
775	
776	
777	
778	
779	
780	
781	
782	
783 784	
785	
786	
787	
788	
789	
790	
791 792	
792 793	
794	
795	
796	
797	
798	
799 800	
800 801	
801	
803	
804	
805	
806	
807 808	
808	
005	

It is made available under a CC-BY-NC-ND 4.0 International license .

## 810 Table 1: Epidemiology of COVID-19 admission in Mucormycosis patients

<b>Baseline characteristics</b>	Total	Discharged	Death	p-valu
	(N=59)	( <b>n=44</b> )	( <b>n=15</b> )	
	n (%)	n (%)	n (%)	
Age (Years)				0.077
$\leq 60$ years	42 (71.2)	34 (77.3)	8 (53.3)	
> 60 years	17 (28.8)	10 (22.7)	7 (46.7)	
Median (IQR)	52 (41, 61)	50 (40, 58)	57 (42, 65)	0.136
Gender				0.481
Male	47 (79.7)	36 (81.8)	11 (73.3)	
Female	12 (20.3)	8 (18.2)	4 (26.7)	
Co-morbidities				
Diabetes Mellitus				0.216
Non-diabetic	6 (10.2)	5 (11.4)	1 (6.7)	
Known Diabetes Mellitus	36 (61.0)	24 (54.5)	12 (80.0)	
Newly diagnosed DM/ IFG	17 (28.8)	15 (34.1)	2 (13.3)	
Hypertension	24 (40.7)	17 (38.6)	7 (46.7)	0.585
Chronic kidney disease	9 (15.3)	6 (13.6)	3 (20.0)	0.680
Ischemic Heart Disease	7 (11.9)	4 (9.1)	3 (20.0)	0.355
Chronic liver disease	2 (3.4)	0 (0.0)	2 (13.3)	0.061
Stroke	1 (1.7)	0 (0.0)	1 (6.7)	0.254
HIV/ Hepatitis B infection	1 (1.7)	1 (2.3)	0 (0.0)	>0.99
Obesity	2 (3.4)	1 (2.3)	1 (6.7)	0.447
Hypo/hyperthyroidism	3 (5.1)	2 (4.5)	1 (6.7)	>0.99
Severity of COVID-19				0.223
Mild	16 (27.1)	12 (27.3)	4 (26.7)	
Moderate	29 (49.2)	24 (54.5)	5 (33.3)	
Severe	14 (23.7)	8 (18.2)	6 (40.0)	
HRCT chest COVID severity score				0.047
< 18	55 (93.2)	43 (97.7)	12 (80.0)	
$\geq 18$	4 (6.8)	1 (2.3)	3 (20.0)	
Median (IQR)	12 (8, 15)	12 (8, 14)	14 (8, 17)	0.152
COVID-19 admission Median(IQR)				
Duration of hospitalization (days)	9 (6, 14)	8 (6, 13.5)	10 (7, 15)	0.149
Duration of ICU stay (days)	0 (0, 10)	0 (0, 0)	0 (0, 10)	0.303
Duration of ventilation (days)	0 (0, 10)	0 (0, 0)	0 (0, 10)	0.046
COVID-19 vaccine status				0.826
No vaccination	46 (78.0)	34 (77.3)	12 (80.0)	
AstraZeneca - 1 dose	9 (15.3)	7 (15.9)	2 (13.3)	
AstraZeneca - 2 doses	2 (3.4)	1 (2.3)	1 (6.7)	
Covaxin (Bharat Biotech) - 1 dose	1 (1.7)	1 (2.3)	0 (0.0)	
Covaxin (Bharat Biotech)- 2 dose	1 (1.7)	1 (2.3)	0 (0.0)	

811

814

<sup>812</sup> DM- Diabetes mellitus; IFG- Impaired fasting glucose; HRCT- High resolution computerized

<sup>813</sup> tomography; HIV- Human immunodeficiency virus

# 816 Table 2a: Drugs administered during COVID-19 treatment

Concomitant drugs	Total	Discharged	Death	p-value
	(N=59)	( <b>n=44</b> )	(n=15)	
	n (%)	n (%)	n (%)	
Meropenem	18 (30.5)	13 (29.5)	5 (33.3)	0.783
Teicoplanin	12 (20.3)	7 (15.9)	5 (33.3)	0.148
Clindamycin	0 (0.0)	0 (0.0)	0 (0.0)	
Doxycycline	25 (42.4)	19 (43.2)	6 (40.0)	0.829
Ivermectin	16 (27.1)	13 (29.5)	3 (20.0)	0.473
Piperacillin-Tazobactam	34 (57.6)	24 (54.5)	10 (66.7)	0.412
Polymyxin	2 (3.4)	0 (0.0)	2 (13.3)	0.061
Fluconazole	12 (20.3)	7 (15.9)	5 (33.3)	0.148
Caspofungin	2 (3.4)	0 (0.0)	2 (13.3)	0.061
Favipravir	35 (59.3)	25 (56.8)	10 (66.7)	0.503
Remdesivir	40 (67.8)	29 (65.9)	11 (73.3)	0.595
Hydroxychloroquine (HCQ)	0 (0.0)	0 (0.0)	0 (0.0)	
Azithromycin	4 (6.8)	4 (9.1)	0 (0.0)	0.564
Lopinavir/ritonavir	0 (0.0)	0 (0.0)	0 (0.0)	
Famotidine	0 (0.0)	0 (0.0)	0 (0.0)	
Enoxaparin	52 (88.1)	37 (84.1)	15 (100)	0.174
Immunomodulator therapy				
Not given	46 (78)	36 (81.8)	10 (66.7)	
Itolizumab	1 (1.7)	1 (2.3)	0 (0.0)	
Barcitinib	2 (3.4)	2 (4.5)	0 (0.0)	
Bevacizumab	2 (3.4)	2 (4.5)	0 (0.0)	
Bevacizumab+Infliximab	1 (1.7)	1 (2.3)	0 (0.0)	
Idofinib	1 (1.7)	1 (2.3)	0 (0.0)	
Infliximab	1 (1.7)	0 (0.0)	1 (6.7)	
Tocilizumab	5 (8.5)	1 (2.3)	4 (26.7)	
Convalescent Plasma	4 (6.8)	3 (6.8)	1 (6.7)	>0.999
Pirfenidone	12 (20.3)	6 (13.6)	6 (40.0)	0.028
Nintedanib	10 (16.9)	5 (11.4)	5 (33.3)	0.050
Dialysis	1 (1.7)	0 (0.0)	1 (6.7)	0.254
Noradrenaline	3 (5.1)	0 (0.0)	3 (20.0)	0.014
Vasopressin	1 (1.7)	0 (0.0)	1 (6.7)	0.254

It is made available under a CC-BY-NC-ND 4.0 International license .

Steroids/Oxygen use in COVID-19 treatment	Total	Discharged	Death	p-value
	(N=59)	(n=44) n (%)	(n=15)	
	n (%)		n (%)	
Steroids given for treating COVID-19				
Methylprednisolone	54 (91.5)	40 (90.9)	14 (93.3)	>0.999
Dexamethasone	4 (6.8)	4 (9.1)	0 (0.0)	0.564
Oral Prednisolone	10 (16.9)	8 (18.2)	2 (13.3)	>0.999
Oral Deflazacort	1 (1.7)	1 (2.3)	0 (0.0)	>0.999
Oxygen given during treatment of COVID-	19			
Nasal oxygen by prongs	5 (8.5)	5 (11.4)	0 (0.0)	0.315
Nasal oxygen by face mask	1 (1.7)	0 (0.0)	1 (6.7)	0.254
Nasal oxygen by NRBM	28 (47.5)	21 (47.7)	7 (46.7)	0.943
NRBM (days) Median (IQR)	7 (4, 10)	5 (4, 10)	7 (7, 10)	0.369
HFNO	2 (3.4)	1 (2.3)	1 (6.7)	0.447
HFNO (days) Median (IQR)	14 (10, 17)	17 (17, 17)	10 (10, 10)	0.317
NIV	7 (11.9)	3 (6.8)	4 (26.7)	0.062
NIV (days) Median (IQR)	8 (3, 15)	3 (3, 15)	9 (5, 14)	0.721
Invasive mechanical ventilation (IMV)	3 (5.1)	0 (0.0)	3 (20.0)	0.014
IMV (days) Median (IQR)	2 (1, 4)	0 (0, 0)	2 (1, 4)	

#### 819 Table 2b: Steroids and Supplemental Oxygen used during COVID-19 treatment

820 NRBM- Non re-breathing mask; IQR- Inter-quartile range; HFNO-High flow nasal oxygen; NIV- Non-

821 invasive ventilation; IMV- Invasive mechanical ventilation

It is made available under a CC-BY-NC-ND 4.0 International license .

# 835 Table 3: Baseline characteristics of patients of Mucormycosis

Mucormycosis	Total	Discharged	Death	p-value
	n (%)	n (%)	n (%)	
Total patients	59	44 (74.6)	15 (25.4)	0.0002
Type of Mucormycosis				<0.0001
Rhinal involvement only	24 (40.7)	24 (54.5)	0 (0.0)	
Rhinal + Orbital involvement	8 (13.6)	7 (15.9)	1 (6.7)	
Rhinal + Orbital + Cerebral	25 (42.4)	13 (29.5)	12 (80.0)	
Rhinal + Cerebral	1 (1.7)	0 (0.0)	1 (6.7)	
Renal	1 (1.7)	0 (0.0)	1 (6.7)	
Symptoms of Mucormycosis				
Facial pain	42 (71.2)	32 (72.7)	10 (66.7)	0.654
Facial swelling	33 (55.9)	22 (50.0)	11 (73.3)	0.142
Headache	43 (72.9)	32 (72.7)	11 (73.3)	>0.999
Eye swelling	33 (55.9)	20 (45.5)	13 (86.7)	0.007
Eye pain	29 (49.2)	17 (38.6)	12 (80.0)	0.007
Loss of vision	21 (35.6)	9 (20.5)	12 (80.0)	<0.000
Ptosis	21 (35.6)	11 (25.0)	10 (66.7)	0.004
Deviation of angle of mouth	5 (8.5)	3 (6.8)	2 (13.3)	0.593
Nasal discharge	15 (25.4)	13 (29.5)	2 (13.3)	0.310
Limb weakness	5 (8.5)	1 (2.3)	4 (26.7)	0.013
Toothache	27 (45.8)	24 (54.5)	3 (20.0)	0.034
<b>Duration of symptoms (days)</b> Median (IQR)	6 (3, 9)	6 (3, 10)	5 (3, 8)	0.488
Duration between 1st positive COVID-19 test and Mucormycosis diagnosis				0.751
< 7 days	2 (3.4)	2 (4.5)	0 (0.0)	
7-14 days	20 (33.9)	14 (31.8)	6 (40.0)	
15-28 days	28 (47.5)	20 (45.5)	8 (53.3)	
> 28 days	9 (15.3)	8 (18.2)	1 (6.7)	
Median (IQR)	17 (12, 22)	17 (13, 23)	17 (10, 21)	0.676

836 IQR- Interquartile range

837			
838			
839			
840			
841			
842			
843			
844			
845			
846			

It is made available under a CC-BY-NC-ND 4.0 International license .

## 847 Table 4: Baseline investigations during admission for Mucormycosis

<b>Baseline characteristics</b>	Total	Discharged	Death	p-value
	(N=59)	( <b>n=44</b> )	( <b>n=15</b> )	
	n (%)	n (%)	n (%)	
Laboratory investigations				
Hemoglobin (g/dL)	13.4 (11.4, 14.5)	13.75 (12.05, 14.5)	12.5 (10.9, 13.9)	0.169
	10400	10150	11900	
WBC (per microliter)	(7000, 14400)	(7000, 13500)	(7000, 15400)	0.568
Absolute Neutrophil count (ANC)	8100	7902	9559	0.447
······································	(5248, 11475)	(5214, 11260)	(5250, 13490)	
Platelet count	227000	231000	198000	0.186
	(178000, 308000)	(189000, 308500)	(160000, 308000)	
Total Bilirubin (mg/dL)	1.035	1.06	0.905	0.369
	(0.83, 1.36) 0.315	(0.85, 1.335) 0.325	(0.7, 1.41) 0.295	
Direct Bilirubin conjugated (mg/dL)	(0.26, 0.46)	(0.26, 0.46)	(0.24, 0.6)	0.601
SGOT (units/L)	31 (18, 50)	28 (18, 40)	45 (32, 53)	0.054
SGPT (units/L)	35 (23, 52)	35 (22, 45)	47.5 (33, 99)	0.071
Blood urea level (mg/dL)	32 (22, 54)	28 (20.5, 49)	41 (27, 92)	0.030
Serum Creatinine (mg/dL)	1.1 (0.96, 1.27)	1.085 (0.96, 1.205)	1.12 (1.02, 1.61)	0.261
Potassium (mmol/L)	4 (3.5, 4.5)	4 (3.5, 4.4)	3.9 (3.2, 4.5)	0.656
Absolute Lymphocyte count (ALC,	4 (3.3, 4.3)	+ (3.3, 4.4)	5.7 (5.2, 4.5)	0.050
cells/mm3)				
< 1000	14 (24.6)	8 (18.2)	6 (46.2)	
$\geq 1000$	43 (75.4)	36 (81.8)	7 (53.8)	
	1250		1045	
Median (IQR)	1350 (1010, 1750)	1407.5 (1185, 1996.5)	1045 (595, 1308)	0.008
Procalcitonin (ng/mL)	(1010, 1750)	(1105, 1990.5)	(595, 1500)	
< 0.05	1 (2.5)	0 (0)	1 (9.1)	
0.05-2.0	28 (70)	22 (75.9)	6 (54.5)	
> 2.0	11 (27.5)	7 (24.1)	4 (36.4)	
Median (IQR)	0.38	0.392	0.341	
Wedian (IQR)	(0.2085, 2.735)	(0.207, 1.56)	(0.212, 3.81)	0.797
C-reactive Protein (mg/L)	(0.2003, 2.735)	(0.207, 1.50)	(0.212, 5.01)	
0-6	2 (4.7)	2 (6.3)	0 (0)	
7-49	9 (20.9)	8 (25)	1 (9.1)	
$\geq 50$	32 (74.4)	22 (68.8)	10 (90.9)	
	84.7	74.25	173.735	
Median (IQR)	(41, 167)	(39, 138.75)	(64.3, 207.5)	0.032
Ferritin (mcg/L)	(11, 107)	(0), 100110)	(0.110, 20110)	
15-150	3 (9.4)	3 (12.5)	0 (0)	
151-1000	16 (50)	13 (54.2)	3 (37.5)	
> 1000	13 (40.6)	8 (33.3)	5 (62.5)	
2 1000	857.1	677.25	1346.5	
Median (IQR)	(280.5, 1429)	(262.55, 1108)	(720.55, 1817.5)	0.089
D-Dimer (mcg/mL)			,	
< 252	9 (24.3)	7 (25.9)	2 (20)	
253-1000	17 (45.9)	13 (48.1)	4 (40)	
> 1000	11 (29.7)	7 (25.9)	4 (40)	
	483.5	427.1	566.9	
Median (IQR)	(253.73, 1201.00)	(237.08, 1071.71)	(255.48, 20)	0.321

848 WBC- White blood cell; IQR- Interquartile range; SGPT- Serum glutamate pyruvate transaminase;

849 SGOT- Serum glutamate oxaloacetate transaminase.

850	Table 5: Treatment regimens used in Mucormycosis

	Total	Discharged	Death	p-value	
Treatment regimen for Mucormycosis	(N=59)	(n=44)	(n=15)	p-value	
	n (%)	(n=44) n (%)	(n=15) n (%)		
Drugs administered					
Liposomal Amphotericin B	53 (89.8)	42 (95.5)	11 (73.3)	0.032	
Amphotericin B lipid complex/emulsion	17 (28.8)	17 (38.6)	0 (0.0)	0.003	
Amphotericin B de-oxycholate	27 (45.8)	22 (50)	5 (33.3)	0.263	
Total Amphotericin days			~ /	0.015	
Not given	5 (8.5)	1 (2.3)	4 (26.7)		
$\leq 21 \text{ days}$	30 (50.8)	20 (45.5)	10 (66.7)		
> 21 days	24 (40.7)	23 (52.3)	1 (6.7)		
Median (IQR)	21 (14, 27)	22 (15, 28)	10 (6, 21)	0.004	
Posaconazole	58 (98.3)	44 (100)	14 (93.3)	0.254	
Isavuconazole	5 (8.5)	5 (11.4)	0 (0.0)	0.315	
Antibiotics given	55 (93.2)	40 (90.9)	15 (100.0)	0.564	
Name of antibiotics	, <b>.</b>				
Amoxicillin-Clavulanate	8 (13.6)	8 (18.2)	0 (0.0)		
Cefpodoxime	1 (1.7)	1 (2.3)	0 (0.0)		
Colistin	1 (1.7)	0 (0.0)	1 (6.7)		
Ceftriaxone-disodium edetate-sulbactam	2 (3.4)	2 (4.5)	0 (0.0)		
Cefoperazone-Sulbactum	1 (1.7)	1 (2.3)	0 (0.0)		
Meropenem	28 (47.5)	15 (34.0)	13 (86.7)		
Ceftriaxone	3 (5.1)	3 (6.8)	0 (0.0)		
Cefuroxime	1 (1.7)	1 (2.3)	0 (0.0)		
Piperacillin-Tazobactam	10 (16.9)	9 (20.5)	1 (6.7)		
Surgical procedures					
FESS	56 (94.9)	42(95.4)	14(93.3)	0.781	
Orbital decompression	10 (16.9)	10 (22.7)	0 (0.0)	0.052	
Palatal clearance	1 (1.7)	1 (2.3)	0 (0.0)	>0.999	
Exenteration	13 (22)	6 (13.6)	7 (46.7)	0.008	
Maxillectomy	9 (15.3)	9 (20.5)	0 (0.0)	0.095	
Neurosurgery	5 (8.5)	3 (6.8)	2 (13.3)	0.593	
Oxygenation and Ventilation data					
Nasal oxygen by prongs	1 (1.7)	0 (0.0)	1 (6.7)	0.254	
Nasal oxygen by face mask	0 (0.0)	0 (0.0)	0 (0.0)		
Nasal oxygen by NRBM	5 (8.5)	4 (9.1)	1 (6.7)	>0.999	
NRBM (days) Median (IQR)	13 (12, 14)	13 (12, 14)	ND		
HFNO	0 (0.0)	0 (0.0)	0 (0.0)		
NIV	2 (3.4)	0 (0.0)	2 (13.3)	0.061	
NIV (days) Median (IQR)	2 (1, 2)	0 (0, 0)	2 (1, 2)	0.015	
Invasive mechanical ventilation (IMV)	8 (13.6)	1 (2.3)	7 (46.7)	<0.0001	
IMV (days) Median (IQR)	3 (2, 4)	3 (3, 3)	3 (2, 4)	<0.0001	

It is made available under a CC-BY-NC-ND 4.0 International license .

	ICU admissions Required ICU ICU stay (days) Median (IQR)	18 (30.5) 3 (3, 6)	8 (18.2) 3 (2, 7)	10 (66.7) 4 (3, 5)	<0.0001 <0.0001	
851	FESS – Functional endoscopic si		$\frac{3(2,7)}{1-\text{Non re-b}}$			tile range:
852	HFNO- High flow nasal oxygen;					
853						
854						
855						
856						
857						
858						
859						
860						
861 862						
863						
864						
865						
866						
867						
868						
869						
870						
871						
872						
873						
874						
875						
876 877						
877						
070						

It is made available under a CC-BY-NC-ND 4.0 International license .

# 879 Table 6: Complications in Mucormycosis patients during antifungal therapy

Complications in	Total	Discharged	Death	p-value	
Mucormycosis	(N=59)	( <b>n=44</b> )	(n=15)	-	
	n (%)	n (%)	n (%)		
Complications					
Acute kidney injury	30 (50.8)	22 (50)	8 (53.3)	0.824	
Hypokalemia	52 (88.1)	40 (90.9)	12 (80.0)	0.355	
Hepatitis	20 (33.9)	12 (27.3)	8 (53.3)	0.066	
Fever	46 (78.0)	35 (79.5)	11 (73.3)	0.721	
Chills	45 (76.3)	34 (77.3)	11 (73.3)	0.757	
Loose motions	14 (23.7)	11 (25.0)	3 (20.0)	>0.999	
Vomiting	21 (35.6)	15 (34.1)	6 (40.0)	0.680	
Loss of appetite	46 (78.0)	35 (79.5)	11 (73.3)	0.721	
Abdominal pain	9 (15.3)	5 (11.4)	4 (26.7)	0.213	
Abdominal Distension	2 (3.4)	1 (2.3)	1 (6.7)	0.447	
Thrombophlebitis	35 (59.3)	29 (65.9)	6 (40.0)	0.078	
Stomatitis	20 (33.9)	15 (34.1)	5 (33.3)	0.957	
Pedal edema	14 (23.7)	9 (20.5)	5 (33.3)	0.311	
Anemia	34 (57.6)	22 (50.0)	12 (80.0)	0.068	
Thrombocytopenia	14 (23.7)	6 (13.6)	8 (53.3)	0.002	
Osteomyelitis	11 (18.6)	10 (22.7)	1 (6.7)	0.259	
Stroke/ Cerebritis	15 (25.4)	2 (4.5)	13 (86.7)	<0.0001	

## 894 Table 7: Relative risk of death in Mucormycosis patients

Factors	Relative risk (95% CI)	p-value
Age > 60 years (Ref: $\leq$ 60 years)	2.162 ((0.9300, 5.0251)	0.098
Male (Ref: Female)	0.702 (0.2708, 1.8205)	0.506
Diabetes Mellitus (Ref: Diabetic)		
Newly diagnosed/ pre-diabetic	0.353 (0.0887, 1.4048)	0.052
COVID-19 related factors		
HRCT score $\geq 18$ (Ref: < 18)	3.438 (1.6153, 7.3155)	0.017
Irrational use of steroids (Ref: Rational use)	0.689 (0.2875, 1.6530)	0.407
Not vaccinated against COVID-19 (Ref: vaccinated)	1.130 (0.3743, 3.4139)	0.822
Duration between 1st COVID-19 test and Mucormycosis diagnosis $\geq$ 15 days (Ref: <15 days)	0.892 (0.3670, 2.1676)	0.803
<b>Duration between COVID-19 discharge and Mucormycosis</b> admission $\ge$ 15 days (Ref: <15 days)	0.671 (0.1764, 2.5556)	0.544
Type of Mucormycosis (Ref: Rhino only)		
Rhinal + Orbital	0.455 (0.0690, 3.0048)	0.259
Rhinal + Orbital + Cerebral	5.440 (1.7140, 17.2662)	0.0004
Symptoms of Mucormycosis (Ref: No symptom)		
Facial pain	0.810 (0.3246, 2.0187)	0.663
Facial swelling	2.167 (0.7794, 6.0234)	0.098
Headache	1.023 (0.3802, 2.7539)	0.964
Eye swelling	5.121 (1.2665, 20.7087)	0.002
Eye pain	4.138 (1.3003, 13.1684)	0.003
Loss of vision	7.238 (2.2978, 22.8006)	<0.0001
Ptosis	3.619 (1.4252, 9.1899)	0.005
Deviation of angle of mouth	1.662 (0.5140, 5.3715)	0.482
Nasal discharge	0.451 (0.1148, 1.7733)	0.146
Limb weakness	3.927 (1.9784, 7.7961)	0.001
Toothache	0.296 (0.0932, 0.9422)	0.012
Investigations in Mucormycosis		
Diabetic Ketoacidosis (Ref: No)	3.267 (1.5012, 7.1085)	0.011
Blood urea level	1.023 (1.0013, 1.0452)	0.0002
$ALC \ge 1000 \text{ (Ref: } < 1000)$	0.379 (0.1531, 0.9422)	0.065
Procalcitonin > 2 (Ref: $\leq 2$ )	1.507 (0.5467, 4.1513)	0.460
C-reactive Protein $\geq 50$ (Ref: < 50)	3.438 (0.4949, 23.8759)	0.063
Ferritin > 1000 (Ref: $\leq$ 1000)	2.436 (0.7011, 8.4634)	0.153
D-Dimer > 252 (Ref: $\le$ 252)	1.286 (0.3315, 4.9860)	0.697
<b>Treatment days in Mucormycosis</b> (Ref: $\leq 21$ days)		
Total Amphotericin days > 21 days	0.125 (0.0172, 0.9093)	0.002
Posaconazole > 21 days	0.364 (0.1293, 1.0228)	0.055
Complications in Mucormycosis (Ref: No complication)		
Hepatitis	2.229 (0.9437, 5.2628)	0.079
Thrombophlebitis	0.457 (0.1872, 1.1164)	0.083
Anemia	2.941 (0.9267, 9.3351)	0.067

It is made available under a CC-BY-NC-ND 4.0 International license .


37

Thrombocytopenia	3.674 (1.6211, 8.3244)	0.004
Stroke/ Cerebritis	19.067 (4.8522, 74.9224)	<0.0001

895 ALC- Absolute lymphocyte count

#### It is made available under a CC-BY-NC-ND 4.0 International license .

38



898 Figure 1: Prevalence of risk factors in Mucormycosis patients who died

899

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure 1: Prevalence of risk factors in Mucormycosis patients who died